A parenteral DNA vaccine protects against pneumonic plague

Vaccine

Volumn 28, Issue 18, 2010, Pages 3219-3230

  Yamanaka, Hitoki ^a,c   Hoyt, Teri ^a   Yang, Xinghong ^a   Bowen, Richard ^b   Golden, Sarah ^a   Crist, Kathryn ^a   Becker, Todd ^a   Maddaloni, Massimo ^a   Pascual, David W ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

IgA; Lymphotactin; Mucosal; Pneumonic plague; Vaccines

Indexed keywords

CHOLERA TOXIN; DNA VACCINE; F1 ANTIGEN VIRULENCE ANTIGEN FUSION PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; LYMPHOTACTIN; PLAGUE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOGENICITY; INFECTION RESISTANCE; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION; YERSINIA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; LYMPHOKINES; MICE; MICE, INBRED BALB C; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT FUSION PROTEINS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 77949658888     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.022     Document Type: Article

References (40)

1. Anisimov A.P., Lindler L.E., and Pier G.B. Intraspecific diversity of Yersinia pestis. Clin Microbiol Rev 17 (2004) 434-464
2. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent. Clin Microbiol Rev 10 (1997) 35-66
3. Koirala J. Plague: disease, management, and recognition of act of terrorism. Infect Dis Clin North Am 20 (2006) 273-287
4. Baker E., Sommer H., Foster L.E., and Meyer K.F. Studies on immunisation against plague. J Immunol 68 (1952) 131-145
5. Winter C.C., Cherry W.B., and Moody M.D. An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull WHO 23 (1960) 408-409
6. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C.J., et al. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 (2002) 1017-1024
7. Leary S.E.C., Williamson E.D., Griffin K.F., Russell P., Eley S.M., and Titball R.W. Active immunisation with V-antigen from Yersinia pestis protects against plague. Infect Immun 63 (1995) 2854-2858
8. Miller J., Williamson E.D., Lakey J., Pearce M.J., Jones S.M., and Titball R.W. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and effect of structure on immunogenicity. FEMS Immunol Med Microbiol 21 (1998) 213-221
9. Heath D.C., Anderson G.W., Mauro M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 (1998) 1131-1137
10. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E.C., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12 (1995) 223-230
11. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washing and protects immunized animals against pneumonic plague. Vaccine 15 (1997) 1079-1084
12. Williamson E.D., Sharp G.J.E., Eley S.M., Vesey P.M., Pepper T.C., Titball R.W., et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 14 (1996) 1613-1619
13. Parent M.A., Berggren K.N., Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 73 (2005) 7304-7310
14. Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., and Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun 74 (2006) 3381-3386
15. Philipovskiy A.V., and Smiley S.T. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun 75 (2007) 878-885
16. Kelner G.S., Kennedy J., Bacon K.B., Kleyensteuber S., Largaespada D.A., Jenkins N.A., et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 266 (1994) 1395-1399
17. Kennedy J., Kelne G.S., Kleyensteuber S., Schall T.J., Weiss M.C., Yssel H., et al. Molecular cloning and functional characterization of human lymphotactin. J Immunol 155 (1995) 203-209
18. Hedrick J.A., Saylor V., Figueroa D., Mizoue L., Xun Y., Menon S., et al. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 158 (1997) 1533-1540
19. Hedrick J.A., and Zlotnik A. Lymphotactin. Clin Immunol Immunopathol 87 (1998) 218-222
20. + T lymphocytes. Eur J Immunol 25 (1995) 1744-1748
21. Yoshida T., Imai T., Kakizaki M., Nishimura M., Takagi S., and Yoshie O. Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem 273 (1998) 16551-16554
22. Yoshida T., Izawa D., Nakayama T., Nakahara K., Kakizaki M., Imai T., et al. Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor. FEBS Lett 458 (1999) 37-40
23. Boismenu R., Feng L., Xia Y.Y., Chang J.C., and Havran W.L. Chemokine expression by intraepithelial γδ T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J Immunol 157 (1996) 985-992
24. Lillard Jr. J.W., Boyaka P.N., Hedrick J.A., Zlotnik A., and McGhee J.R. Lymphotactin acts as an innate mucosal adjuvant. J Immunol 162 (1999) 1959-1965
25. Yamanaka H., Hoyt T., Yang X., Golden S., Bosio C.M., Crist K., et al. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun 76 (2008) 4564-4573
26. Maddaloni M., Staats H.F., Mierzejewska D., Hoyt T., Robinson A., Callis G., et al. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A (BoNT/A). J Immunol 177 (2006) 5524-5532
27. Yang X., Hinnebusch B.J., Trunkle T., Bosio C.M., Suo Z., Tighe M., et al. Oral vaccination with Salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol 178 (2007) 1059-1067
28. Yang X., Hudson M., Walters N., Bargatze R.F., and Pascual D.W. Selection of protective epitopes for Brucella melitensis using DNA vaccination. Infect Immun 73 (2005) 7297-7303
29. Ochoa-Repáraz J., Riccardi C., Rynda A., Jun S., Callis G., and Pascual D.W. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol 178 (2007) 1791-1799
30. Pascual D.W., Trunkle T., and Sura J. Fimbriated Salmonella enterica serovar Typhimurium abates initial inflammatory responses by macrophages. Infect Immun 70 (2002) 4273-4281
31. Yamanaka H., Hoyt T., Bowen R., Yang X., Crist K., Golden S., et al. An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague. Vaccine 27 (2009) 80-87
32. Cao X., Zhang W., He L., Xie Z., Ma S., Tao Q., et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 161 (1998) 6238-6244
33. Dilloo D., Bacon K., Holeden W., Zhong W., Burdach S., Zlotnik A., et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 2 (1996) 1090-1095
34. Waterman P.M., Kitabwalla M., Hatfield G.S., Evans P.S., Lu Y., Tikhonov I., et al. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates. Viral Immunol 17 (2004) 545-557
35. Min W., Lillehoj H.S., Burnside J., Weining K.C., Staeheli P., and Zhu J.J. Adjuvant effects of IL-1β, IL-2 IL-8, IL-15, IFN-α, IFN-γ, TGF-β4 and lymphotactin on DNA vaccination against Eimeria ecervulina. Vaccine 20 (2002) 267-274
36. Egan M.A., Chong S.Y., Megati S., Montefiori D.C., Rose N.F., Boyer J.D., et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 21 (2005) 629-643
37. Pal V.S., Kalyanaraman B., Nair B.C., Whitney S., Keen T., Hocker L., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 (2006) 341-353
38. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155 (1995) 4621-4629
39. Vajdy M., Kosco-Vilbois M.H., Kopf M., Kohler G., and Lycke N. Impaired mucosal immune responses in interleukin 4-targeted mice. J Exp Med 181 (1995) 41-53
40. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., and Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 116 (1999) 107-114